(1-s--2s)-4-amino-n-(1--carbamoyl-2--phenylethyl)-2-(4---methyl-1---naphthalenesulfonylamino)butanamide and Disease-Models--Animal

(1-s--2s)-4-amino-n-(1--carbamoyl-2--phenylethyl)-2-(4---methyl-1---naphthalenesulfonylamino)butanamide has been researched along with Disease-Models--Animal* in 2 studies

Other Studies

2 other study(ies) available for (1-s--2s)-4-amino-n-(1--carbamoyl-2--phenylethyl)-2-(4---methyl-1---naphthalenesulfonylamino)butanamide and Disease-Models--Animal

ArticleYear
Somatostatin receptor subtype 4 activation is involved in anxiety and depression-like behavior in mouse models.
    Neuropharmacology, 2016, Volume: 101

    Somatostatin regulates stress-related behavior and its expression is altered in mood disorders. However, little is known about the underlying mechanisms, especially about the importance of its receptors (sst1-sst5) in anxiety and depression-like behavior. Here we analyzed the potential role of sst4 receptor in these processes, since sst4 is present in stress-related brain regions, but there are no data about its functional relevance. Genetic deletion of sst4 (Sstr4(-/-)) and its pharmacological activation with the newly developed selective non-peptide agonist J-2156 were used. Anxiety was examined in the elevated plus maze (EPM) and depression-like behavior in the forced swim (FST) and tail suspension tests (TST). Neuronal activation during the TST was monitored by Fos immunohistochemistry, receptor expression was identified by sst4(LacZ) immunostaining in several brain regions. Sstr4(-/-) mice showed increased anxiety in the EPM and enhanced depression-like behavior in the FST. J-2156 (100 μg/kg i.p.) exhibited anxiolytic effect in the EPM and decreased immobility in the TST. J-2156 alone did not influence Fos immunoreactivity in intact mice, but significantly increased the stress-induced Fos response in the dorsal raphe nucleus, central projecting Edinger-Westphal nucleus, periaqueductal gray matter, the magnocellular, but not the parvocellular part of the hypothalamic paraventricular nucleus, lateral septum, bed nucleus of the stria terminalis and the amygdala. Notably, sst4(LacZ) immunoreactivity occurred in the central and basolateral amygdala. Together, these studies reveal that sst4 mediates anxiolytic and antidepressant-like effects by enhancing the stress-responsiveness of several brain regions with special emphasis on the amygdala.

    Topics: Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Brain; Butanes; Depression; Disease Models, Animal; Exploratory Behavior; Gene Expression Regulation; Hindlimb Suspension; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Naphthalenes; Oncogene Proteins v-fos; Receptors, Somatostatin; Sulfones; Swimming

2016
The somatostatin receptor 4 agonist J-2156 reduces mechanosensitivity of peripheral nerve afferents and spinal neurons in an inflammatory pain model.
    European journal of pharmacology, 2015, Jan-05, Volume: 746

    Somatostatin (SST) is a peptide hormone that regulates the endocrine system and affects neurotransmission via interaction with G protein-coupled SST receptors and inhibition of the release of different hormones. The aim of this study was to investigate whether the analgesic properties of the selective SSTR4 agonist J-2156 are mediated via peripheral and/or spinal receptors. Effect on mechanical hyperalgesia in the Complete Freund׳s Adjuvant (CFA) model was measured after intraperitoneal application of J-2156. Electrophysiological neuronal recordings were conducted 24 h after injection of CFA or vehicle into the paw of Wistar rats. Mechanosensitivity of peripheral afferents of the saphenous nerve as well as of spinal wide dynamic range (WDR) and nociceptive-specific (NS) neurons were measured after systemic or spinal application of J-2156. In CFA animals J-2156 dose dependently reduced hyperalgesia in behavioral studies. The minimal effective dose was 0.1 mg/kg. Mechanosensitivity of peripheral afferents and spinal neurons was significantly reduced by J-2156. NS neurons were dose dependently inhibited by J-2156 while in WDR neurons only the highest concentration of 100 µM had an effect. In sham controls, J-2156 had no effect on neuronal activity. We demonstrated that J-2156 dose-dependently reduces peripheral and spinal neuronal excitability in the CFA rat model without affecting physiological pain transmission. Given the high concentration of the compound required to inhibit spinal neurons, it is unlikely that the behavioral effect seen in CFA model is mediated centrally. Overall these data demonstrated that the analgesic effect of J-2156 is mediated mainly via peripheral SST4 receptors.

    Topics: Administration, Cutaneous; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Butanes; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophysiological Phenomena; Hyperalgesia; Injections, Intraperitoneal; Injections, Intravenous; Male; Mechanoreceptors; Naphthalenes; Neuritis; Neurons, Afferent; Nociceptors; Peripheral Nerves; Rats, Wistar; Receptors, Somatostatin; Spinal Nerves; Sulfones

2015